• FDA approved Merck KGaA’s PIMJETMI for adults with symptomatic tenosynovial giant cell tumor when surgery risks worsening functional limitation or severe morbidity.
• The once-daily oral treatment achieved a 56% objective response rate at week 25 versus 3% for placebo in Phase 3 testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief via Business Wire (Ref. ID: 202611101423BIZWIRE_USPR_____20261029_BW447931) on November 10, 2026, and is solely responsible for the information contained therein.